<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04799418</url>
  </required_header>
  <id_info>
    <org_study_id>SNS-PD-003</org_study_id>
    <nct_id>NCT04799418</nct_id>
  </id_info>
  <brief_title>STEM-PD Open Label Extension (OLE)</brief_title>
  <official_title>Non-Invasive Brainstem Modulation for the Treatment of Non-Motor Symptoms in Parkinson's Disease: An Open Label Extension (OLE) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scion NeuroStim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Scion NeuroStim</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to establish the safety and efficacy of extended twice daily treatments for&#xD;
      treating symptoms associated with PD. Only participants who completed the STEM-PD RCT trial&#xD;
      are eligible for the OLE.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 220 participants will enter an open label extension (OLE) study during which all study&#xD;
      participants will receive treatment for 12 weeks (84 days). Study participants will be&#xD;
      followed for 16 weeks (112 days) post treatment-cessation and then the twice daily treatments&#xD;
      will be re-introduced for the final 8 weeks (56 days).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MDS-NMS Assessment</measure>
    <time_frame>3 months</time_frame>
    <description>The change in the International Parkinson and Movement Disorder Society Non-Motor Rating Scale (MDS-NMS) total score at the end of the treatment period.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Parkinson Disease</condition>
  <condition>Parkinson's Disease and Parkinsonism</condition>
  <arm_group>
    <arm_group_label>Experimental Treatment 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study participants will self-administer ~19-minute treatments twice daily in the home setting using a non-invasive brainstem modulation device. The device has been deemed as a nonsignificant risk for studies in Parkinson's disease by the United States Food and Drug Administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Open Label Extension Study</intervention_name>
    <description>This study will investigate the safety and efficacy of extended treatments for the management of symptoms related to PD.</description>
    <arm_group_label>Experimental Treatment 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Completion of the study activities in the STEM-PD RCT trial. l.&#xD;
&#xD;
          -  Participants must be willing and able to give consent to participate in the study&#xD;
             trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant anticipates being unable to attend all visits and complete all study&#xD;
             activities in both the RCT and OLE study trial.&#xD;
&#xD;
          -  Women of child-bearing potential who are pregnant or plan to become pregnant during&#xD;
             the course of the RCT or OLE study trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kara Richardson</last_name>
    <phone>984-884-1020</phone>
    <email>krichardson@scionneurostim.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nickie Jackson</last_name>
    <email>njackson@scionneurostim.com</email>
  </overall_contact_backup>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 11, 2021</study_first_submitted>
  <study_first_submitted_qc>March 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2021</study_first_posted>
  <last_update_submitted>March 11, 2021</last_update_submitted>
  <last_update_submitted_qc>March 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Open Label Extension Study</keyword>
  <keyword>Medical Devices</keyword>
  <keyword>Non-Motor Symptoms (NMS)</keyword>
  <keyword>Non-Invasive Brain Stimulation</keyword>
  <keyword>Parkinson Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Parkinsonian Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

